The Efficacy of Topical Serum X for Skin Brightening

November 27, 2023 updated by: Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre

The Efficacy of Topical Serum X Containing Arbutin and Glutathione for Skin Brightening

This study is conducted to evaluate the effectiveness of topical serum X containing arbutin and glutathione for skin brightening. The study duration is 12 weeks and the skin assessment will be carried out at baseline, week 4, 8 and week 12.The main questions this study aims to answer are:

  1. The skin brightening effect of the product on facial skin.
  2. To observe any adverse effect occurrence with the usage of the product.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Malaysia
    • Selangor
      • Petaling Jaya, Selangor, Malaysia, 47810
        • Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Malaysia citizen
  • Male and female (age 18-30 years old)

Exclusion Criteria:

  • Participant with severe acne skin condition
  • Participant who is taking isotretinoin, immunocompromised patients and received laser and light treatment within the last three months
  • Participant who undergo whitening or cosmetic treatments such as botox and dermal fillers within the previous six month
  • Participant with a history of facial surgery such as facelift or nose reshaping
  • Participant with history of allergies to any ingredient in the study product
  • Participant who is pregnant or plan to get pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Serum X
Participants will used serum X twice daily for 12 weeks
Other: Other: Serum X
Serum X contain arbutin and glutathione

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in skin tone from baseline and at week 4, week 8, and week 12 after usage of serum X.
Time Frame: Baseline and at week 4, week 8, and week 12
Skin tone will be assessed using JANUS III skin analyzer
Baseline and at week 4, week 8, and week 12
Adverse effect after using serum X
Time Frame: Week 12
Based on adverse effect occurrence on participants that occur during study period (12 weeks
Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2022

Primary Completion (Actual)

May 31, 2023

Study Completion (Actual)

September 1, 2023

Study Registration Dates

First Submitted

January 11, 2023

First Submitted That Met QC Criteria

January 11, 2023

First Posted (Actual)

January 23, 2023

Study Record Updates

Last Update Posted (Actual)

November 29, 2023

Last Update Submitted That Met QC Criteria

November 27, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • UMRAMREC001-22

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe